Product How it works Pricing Blog FAQ About Contact
Español English
EspañolEnglish
Log inCreate free account
Altimmune

Altimmune (NASDAQ: ALT) insider transactions

In the twelve months to 10 November 2026, executives and directors of Altimmune reported 0 open-market sales and 11 open-market purchases of 105,227 shares ($370,120), by 6 people, according to the Form 4 filings they submitted to the SEC.

Latest transactions

The 20 most recent transactions in Altimmune shares reported on Form 4
DateInsiderRoleTransactionSharesPriceHeld afterFiling
1 October 2026Weaver Gregory LChief Financial OfficerOption exercise+14,475—54,306Form 4
1 October 2026Weaver Gregory LChief Financial OfficerShares withheld for tax−4,379$2.7649,927Form 4
1 October 2026Arbet-Engels ChristopheChief Medical OfficerOption exercise+37,500—37,500Form 4
1 October 2026Arbet-Engels ChristopheChief Medical OfficerShares withheld for tax−12,679$2.7624,821Form 4
16 September 2026Richardson Linda MChief Commercial OfficerOption exercise+24,000—24,000Form 4
16 September 2026Richardson Linda MChief Commercial OfficerShares withheld for tax−6,826$3.2417,174Form 4
13 August 2026Durso Jerome BenedictPresident and CEOOpen-market purchase+15,000$2.9562,500Form 4
31 July 2026Weaver Gregory LChief Financial OfficerGrant or award+1,753$2.4139,831Form 4
31 July 2026Roberts M ScotChief Scientific OfficerGrant or award+875$2.41113,699Form 4
6 April 2026Gill JohnDirectorOpen-market purchase+9,200$3.4121,700Form 4
1 April 2026Weaver Gregory LChief Financial OfficerOpen-market purchase+10,000$3.1538,078Form 4
1 April 2026Durso Jerome BenedictPresident and CEOOpen-market purchase+15,000$3.1447,500Form 4
6 March 2026Weaver Gregory LChief Financial OfficerOpen-market purchase+5,000$3.5428,078Form 4
6 March 2026Durso Jerome BenedictPresident and CEOOpen-market purchase+20,000$3.5432,500Form 4
2 February 2026Roberts M ScotChief Scientific OfficerOption exercise+7,775—115,153Form 4
2 February 2026Roberts M ScotChief Scientific OfficerShares withheld for tax−2,329$5.55112,824Form 4
31 January 2026Roberts M ScotChief Scientific OfficerGrant or award+5,567$3.07107,378Form 4
31 January 2026Garg Vipin KDirectorGrant or award+6,926$3.07424,519Form 4
31 January 2026Jordt Raymond MChief Business OfficerGrant or award+4,571$3.0770,107Form 4
30 January 2026Roberts M ScotChief Scientific OfficerOption exercise+9,275—104,670Form 4

Names appear as in the filing, surname first. A dash in the price column means the filing reports none, as in grants and gifts.

How to read the table

Only open-market purchases and sales are trades the insider chose to make at the market price, and they are the ones counted in the summary above. Grants, option exercises and shares withheld for tax come from pay plans. A sale marked as a 10b5-1 plan was scheduled in advance under a written plan.

Where each row comes from

From the Form 4 that each executive, director or large shareholder must file with the SEC within two business days of a transaction, read up to 10 November 2026. Each row links to its filing on EDGAR. Only transactions in shares are listed, not derivatives, and amended filings are left out. The accounts of the company are on the Altimmune page; the method, in data sources.

Information prepared from the Form 4 filings submitted to the SEC, for information purposes only. It is not financial advice or a recommendation to buy or sell. Updated on 12 November 2026.